Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events

Area of Science:

• Cardiovascular Medicine
• Biomarkers
• Clinical Chemistry

Background:

• Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase.
• Elevated ADMA levels are associated with endothelial dysfunction and cardiovascular disease.
• The clinical significance of ADMA in unstable angina (UA) requires further investigation.

Purpose of the Study:

• To investigate the association between ADMA levels and clinical outcomes in patients with unstable angina.
• To determine if changes in ADMA levels after percutaneous coronary intervention (PCI) correlate with cardiovascular event recurrence.

Main Methods:

• Prospective study including 36 UA patients, 45 stable angina (SA) patients, and 40 controls.
• ADMA levels measured at baseline and 6 weeks post-PCI using ELISA.
• 1-year follow-up for major adverse cardiovascular events (MACE).

Main Results:

• Baseline ADMA was significantly higher in CAD patients than controls (0.76 vs. 0.59 μmol/L).
• UA patients had higher baseline ADMA than SA patients (0.82 vs. 0.73 μmol/L; P=0.01).
• UA patients without recurrent events showed a significant ADMA reduction post-PCI (0.81 to 0.73 μmol/L).
• Persistently elevated ADMA correlated with a higher MACE rate.

Conclusions:

• ADMA is significantly elevated in patients with unstable angina.
• A decrease in ADMA levels 6 weeks after PCI may indicate a lower risk of recurrent cardiovascular events.
• ADMA serves as a potential biomarker for predicting clinical outcomes in UA patients.